Mitigare® True Blue Savings covers branded colchicine capsules and authorized generic colchicine capsules. 

  • Mitigare® (colchicine) 0.6 mg capsules are the only capsules indicated for prophylaxis of gout flares in adults.
  • When you receive a brand-specific Mitigare® prescription, you have the option to substitute with authorized generic colchicine capsules.
  • Keep in mind, non-capsule versions of colchicine cannot be substituted when a prescription is written for Mitigare® capsules.
  • COMING SOON: 30-count bottle for ease of dispensing.

Download the updated Mitigare® Pharmacy Sell Sheet.

Mitigare® is the True Blue Choice

Don’t forget to replenish your inventory of Mitigare® (colchicine) 0.6 mg capsules and authorized generic colchicine 0.6 mg capsules. Adults living with gout will appreciate this affordable gout flare prevention option.

Mitigare® (Colchicine) 0.6 mg Capsules

ProductNDC#BottleABCCardinalMcKessonMorris & Dickson
Mitigare® 0.6 mg Capsules59467-318-01100 ct1016030151975793506151882332
Mitigare® 0.6 mg Capsules59467-318-101,000 ct1016030051975953506177not available

Authorized Generic Colchicine 0.6 mg Capsules

ProductNDC#BottleABCCardinalHD SmithMcKessonMorris & Dickson
Colchicine 0.6 mg Capsules0143-3018-01100 ct10144830505294951624743293446200048
Colchicine 0.6 mg Capsules0143-3018-101,000 ct10144831not available51624823293412not available

True Blue Savings for Eligible Patients

With the Mitigare® True Blue Savings card, eligible adult patients can:

  • Receive Mitigare® (colchicine) free for 30 days and get $5 refills.*
  • Redeem the co-pay card for Mitigare® capsules or authorized generic colchicine capsules
  • Count on the Lowest Wholesale Acquisition Cost (WAC)1

*For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are free only for eligible patients. Maximum savings of $65 on the first fill and $50 on refills. Review the Terms and Conditions and eligibility requirements.

References

  1. First Databank. AnalySource website. Available at: https://www.analysource.com/. Accessed January 2, 2018

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.